接受雄激素受体抑制剂阿帕他胺治疗的前列腺癌患者的皮肤不良事件
研究评估303例接受阿帕他胺治疗的前列腺癌患者,71例(23.4%)发生皮肤不良事件,中位发生时间77天。大多数为1/2级,可用局部±口服激素管理;临床试验患者报告皮肤不良事件的风险更高(OR=5.1)。
要点
- 303例接受阿帕他胺治疗的患者中,23.4%发生皮肤不良事件,中位发生时间77天。
- 常见皮肤不良事件为斑丘疹(33.8%)和皮肤干燥症(32.4%)。
- 临床试验患者报告皮肤不良事件的风险高于非试验环境患者(OR=5.1)。
核心结论
- 阿帕他胺相关皮肤不良事件常见,可用局部±口服激素管理;随着阿帕他胺适应症扩大,皮肤不良事件的识别和管理至关重要。
研究设计与样本
- 评估303例接受阿帕他胺治疗的前列腺癌患者,计算皮肤不良事件频率和发生时间,描述临床病理特征和管理,并使用逻辑回归模型分析皮肤不良事件发生与临床试验参与及阿比特龙/泼尼松暴露的关联。
主要发现
- 71例(23.4%)患者发生任何级别的皮肤不良事件,中位发生时间为暴露后77天(IQR:30-135)。
- 20例(6.6%)因皮肤不良事件中断治疗,包括8例(2.6%)再次挑战时维持剂量、7例(2.3%)剂量降低和5例(1.7%)停药。
- 常见皮肤不良事件为斑丘疹(33.8%)和皮肤干燥症(32.4%)。
- 9例皮肤活检组织学分析中7例(77.8%)支持药物反应。
- 皮肤不良事件组与无皮肤不良事件组之间实验室血液学、肝功能和肾功能无显著差异。
关键数值与推荐
- 大多数1/2级皮肤不良事件(29例,40.8%)需要局部激素(14例,19.7%);少数需要口服激素(3例,4.2%)±口服抗组胺药。
- 大多数3级皮肤不良事件(8例,11.3%)需要口服/局部激素(5例,7.0%);少数需要局部激素(3例,4.2%)±口服抗组胺药。
- 临床试验患者(180例,59.4%)比非试验环境患者更可能报告皮肤不良事件(OR=5.1 [95% CI 2.55-10.12];p <0.001)。
- 在临床试验患者中,同时接受阿比特龙/泼尼松者(109/180,60.6%)更可能报告皮肤不良事件(OR=3.1 [95% CI 1.53-6.17];p=0.002)。
临床怎么用
- 阿帕他胺相关皮肤不良事件可用局部±口服激素管理。
- 随着阿帕他胺适应症扩大,皮肤不良事件的识别和管理至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with prostate cancer (PCa) treated with apalutamide frequently develop rash. We aim to characterize apalutamide-related dermatological adverse events (dAEs) and management. MATERIALS AND METHODS: We assessed 303 patients with PCa treated with apalutamide. DAE frequency and time to onset were calculated and clinicopathological features and management described. Associations between dAE occurrence and clinical trial participation, as well as abiraterone/prednisone exposure were detected using logistic regression models. RESULTS: Seventy-one (23.4%) patients had all-grade dAE occurring at a median of 77 (IQR: 30-135) days post-exposure. Twenty (6.6%) dAE-related therapy interruptions included: 8 (2.6%) with dose maintained on rechallenge, 7 (2.3%) with dose reduction and 5 (1.7%) with discontinuation. Common dAEs were maculopapular rashes (33.8%) and xerosis (32.4%). Seven (77.8%) of 9 histological analyses of skin biopsies supported a drug reaction. No significant differences in laboratory hematological, hepatic and renal function were detected between dAE and no dAE cohorts. Most treated grade 1/2 dAEs (29, 40.8%) required topical steroids (14, 19.7%); few required oral steroids (3, 4.2%) ± oral antihistamines. Most grade 3 dAEs (8, 11.3%) required oral/topical steroids (5, 7.0%); few required topical steroids (3, 4.2%) ± oral antihistamines. Clinical trial patients (180, 59.4%) were more likely to report dAEs than those in the off-trial setting (OR=5.1 [95% CI 2.55-10.12]; p <0.001). Of clinical trial patients, concomitant abiraterone/prednisone recipients (109 of 180, 60.6%) were more likely to report dAEs (OR=3.1 [95% CI 1.53-6.17]; p=0.002). CONCLUSIONS: Apalutamide-related dAEs are frequent and can be managed with topical ± oral steroids. With expanded approval of apalutamide, dAE identification and management are essential.
引用
- Pan A, Reingold RE, Zhao JL, et al. Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide. J Urol. 2022. PMID: 35020444. doi:10.1097/JU.0000000000002425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。